Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System
Stereotaxis (NYSE:STXS), a pioneer in surgical robotics, announced that Erasmus Medical Center in Rotterdam has successfully performed its first procedures using the Genesis Robotic Magnetic Navigation System. Erasmus MC, having completed over 4,500 procedures with Stereotaxis technology, becomes the first center in The Netherlands to implement this advanced system.
The Genesis System represents the latest advancement in Robotic Magnetic Navigation technology, designed to treat arrhythmias through cardiac ablation. Dr. Sing-Chien Yap, Director of Electrophysiology at Erasmus Medical Center, highlighted the system's enhanced speed and responsiveness, particularly when combined with the MAGiC Catheter, benefiting patients with complex arrhythmias, including children and those with congenital heart disease.
Stereotaxis (NYSE:STXS), pioniere della robotica chirurgica, ha annunciato che l'Erasmus Medical Center di Rotterdam ha eseguito con successo i primi interventi utilizzando Genesis Robotic Magnetic Navigation System. L'Erasmus MC, che ha completato oltre 4.500 procedure con la tecnologia Stereotaxis, è il primo centro nei Paesi Bassi ad adottare questo sistema avanzato.
Il Genesis System rappresenta l'ultima frontiera della navigazione magnetica robotica, progettata per trattare le aritmie tramite ablazione cardiaca. Il Dr. Sing-Chien Yap, Direttore dell'Elettrofisiologia all'Erasmus Medical Center, ha sottolineato la maggiore velocità e reattività del sistema, soprattutto quando abbinato al catetere MAGiC, beneficiando pazienti con aritmie complesse, inclusi bambini e persone con cardiopatia congenita.
Stereotaxis (NYSE:STXS), pioneros en robótica quirúrgica, anunció que el Erasmus Medical Center de Rotterdam ha realizado con éxito sus primeros procedimientos con el sistema de navegación magnética robótica Genesis. El Erasmus MC, que ya ha completado más de 4.500 procedimientos con la tecnología de Stereotaxis, se convierte en el primer centro en los Países Bajos en implementar este avanzado sistema.
El sistema Genesis representa el último avance en la tecnología de Navegación Magnética Robótica, diseñado para tratar arritmias mediante la ablación cardíaca. El Dr. Sing-Chien Yap, Director de Electrofisiología del Erasmus Medical Center, destacó la mayor rapidez y capacidad de respuesta del sistema, especialmente cuando se combina con el catéter MAGiC, beneficiando a pacientes con arritmias complejas, incluidos niños y personas con cardiopatía congénita.
Stereotaxis (NYSE:STXS), 수술 로봇공학의 선두주자로서 로테르담의 에라스무스 메디컬 센터가 Genesis Robotic Magnetic Navigation System을 이용한 첫 시술을 성공적으로 수행했다고 발표했습니다. Stereotaxis 기술로 4,500건이 넘는 시술을 마친 Erasmus MC는 네덜륨에서 이 고급 시스템을 도입한 첫 번째 센터가 되었습니다.
Genesis System은 로봇 기반 자력 내비게이션 기술의 최신 진보로, 심장 절제술을 통해 부정맥을 치료하도록 설계되었습니다. 에라스무스 의과센터의 전기생리학 이사인 Sing-Chien Yap 박사는 MAGiC 카테터와 결합될 때 시스템의 속도와 반응성이 향상되어, 복잡한 부정맥을 가진 환자들, 특히 어린이 및 선천성 심질환 환자에게 이익이 된다고 밝혔습니다.
Stereotaxis (NYSE:STXS), pionnier de la robotique chirurgicale, a annoncé que le centre médical Erasmus de Rotterdam a mené avec succès ses premières interventions utilisant le Genesis Robotic Magnetic Navigation System. L'Erasmus MC, ayant réalisé plus de 4 500 procédures avec la technologie Stereotaxis, devient le premier centre aux Pays-Bas à déployer ce système avancé.
Le système Genesis représente la dernière avancée en matière de navigation magnétique robotique, conçue pour traiter les arythmies par ablation cardiaque. Le Dr Sing-Chien Yap, Directeur de l'électrophysiologie à l'Erasmus Medical Center, a souligné la vitesse et la réactivité accrues du système, notamment lorsqu'il est associé au cathéter MAGiC, au bénéfice des patients souffrant d'arythmies complexes, y compris les enfants et les personnes atteintes de malformations cardiaques congénitales.
Stereotaxis (NYSE:STXS), Pionier der chirurgischen Robotik, gab bekannt, dass das Erasmus Medical Center in Rotterdam erfolgreich seine ersten Eingriffe mit dem Genesis Robotic Magnetic Navigation System durchgeführt hat. Das Erasmus MC hat mit der Stereotaxis-Technologie bereits über 4.500 Eingriffe absolviert und ist damit das erste Zentrum in den Niederlanden, das dieses fortschrittliche System einführt.
Das Genesis-System stellt den neuesten Fortschritt in der Robotic-Magnetic-Navigation-Technologie dar und ist darauf ausgelegt, Arrhythmien durch eine kardiale Ablation zu behandeln. Dr. Sing-Chien Yap, Direktor der Elektrophysiologie am Erasmus Medical Center, hob die erhöhte Geschwindigkeit und Reaktionsfähigkeit des Systems hervor, insbesondere wenn es mit dem MAGiC-Catheter kombiniert wird, und kommt damit Patienten mit komplexen Arrhythmien zugute, einschließlich Kindern und Menschen mit angeborenen Herzfehlern.
Stereotaxis (NYSE:STXS)، رائد الروبوتات الجراحية، أعلن أن مركز Erasmus الطبي في روتردام قد أجرى بنجاح أول إجراءات باستخدام Genesis Robotic Magnetic Navigation System. أصبح Erasmus MC، الذي أتم أكثر من 4,500 إجراء باستخدام تقنيات Stereotaxis، أول مركز في هولندا يعتمد هذا النظام المتقدم.
يمثل نظام Genesis آخر تطور في تكنولوجيا الملاحة المغناطيسية الروبوتية، المصممة لعلاج اضطرابات النظم القلبي عن طريق التطعيم القلبي. وأبرز الدكتور Sing-Chien Yap، مدير الفيزيولوجيا الكهربائية في Erasmus Medical Center، سرعة النظام واستجابته المعززة، لا سيما عندما يُدمج مع catheteri MAGiC، مما يفيد المرضى الذين يعانون من اضطرابات قلبية معقدة، بما في ذلك الأطفال وذوي أمراض قلب خلقية.
Stereotaxis (NYSE:STXS)，作为手术机器人技术的先驱，宣布荷兰鹿特丹的伊拉斯穆斯医学中心已成功完成首次手术，使用Genesis Robotic Magnetic Navigation System系统。该中心在使用Stereotaxis技术完成超过4,500例手术后，成为荷兰首个引入此先进系统的中心。
Genesis系统代表了机器人磁导航技术的最新进展，旨在通过心脏消融治疗心律失常。伊拉斯穆斯医学中心心电生理科主任Yap博士指出，该系统在与MAGiC导管结合时，速度与响应性均得到提升，惠及包括儿童和先天性心脏病患者在内的复杂心律失常患者。
- First successful implementation of Genesis System in The Netherlands, expanding market presence
- Strong track record with over 4,500 procedures performed at Erasmus MC using Stereotaxis technology
- Technology demonstrates enhanced capabilities when combined with MAGiC Catheter
- System shows versatility in treating complex cases including pediatric and congenital heart disease patients
- Significant dependence on third-party vendors as disclosed in risk factors
- Purchase orders subject to contingencies and potential modifications or cancellations
Insights
Erasmus MC's adoption of Stereotaxis' Genesis system strengthens the company's European presence and validates its robotic navigation technology.
The announcement that Erasmus Medical Center has successfully implemented Stereotaxis' Genesis Robotic Magnetic Navigation System represents a significant validation for the company's technology. Erasmus MC is not a newcomer to this technology—having already performed over 4,500 procedures with Stereotaxis systems—making their upgrade to Genesis particularly meaningful as it demonstrates customer retention and technology advancement acceptance.
The implementation in The Netherlands expands Stereotaxis' European footprint, which is strategically important for medical device companies seeking global market penetration. Dr. Yap's comments highlight specific technical improvements that address critical clinical needs, particularly the system's enhanced speed and responsiveness when combined with the MAGiC Catheter.
Most notably, Erasmus' emphasis on using this technology for complex patient populations—including children, congenital heart disease patients, and those with complex arrhythmias—positions Genesis as a specialized solution for challenging cases where precision and safety margins are most critical. This differentiation in difficult-to-treat populations typically commands premium pricing and creates institutional dependency on the technology once adopted.
The 150,000 patient treatment milestone mentioned signals substantial real-world experience, which is crucial for medical technology adoption as it provides evidence of safety and efficacy beyond controlled clinical trials. For a company in the robotic surgery space, this level of clinical usage helps overcome adoption barriers that often plague medical innovations.
ST. LOUIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced successful first procedures by physicians at Erasmus University Medical Center in Rotterdam, The Netherlands, using the advanced Genesis Robotic Magnetic Navigation System.
“We have long recognized the clinical benefits of robotics, and are delighted to be the first in The Netherlands to make the Genesis robotic system available to cardiovascular patients,” said Dr. Sing-Chien Yap, Director of Electrophysiology at Erasmus Medical Center. “We are impressed with the speed and responsiveness of Genesis. Combined with the MAGiC Catheter we are particularly pleased with the synergistic additive improvements to robotic magnetic navigation. These technological advances are important in ensuring we can offer the best care to all arrhythmia patients, including children, patients with congenital heart disease, and patients with complex arrhythmia.”
Erasmus MC has been a global leader in using robotic magnetic navigation for complex arrhythmia procedures, having performed over 4,500 procedures with Stereotaxis technology. The Genesis System is the latest advancement in Robotic Magnetic Navigation technology. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmia may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.
“We appreciate our long-term partnership with the electrophysiology team at Erasmus,” said David Fischel, Stereotaxis Chairman and CEO. “We look forward to continuing to support their successful robotic program and working together to advance technological progress, scientific discovery, and clinical care.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
What is the significance of Erasmus Medical Center adopting Stereotaxis (STXS) Genesis Robotic System?
How does the Stereotaxis (STXS) Genesis System benefit cardiac patients?
What is the market potential for Stereotaxis (STXS) Genesis Robotic System?
How many procedures has Stereotaxis (STXS) technology been used for globally?
What are the key features of Stereotaxis (STXS) Genesis Robotic System at Erasmus MC?
